{"id":"W4388902238","doi":"10.1007/s40259-023-00630-5","title":"Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Celltrion","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Clinical endpoint; Biosimilar; Dosing; Adverse effect; Randomized controlled trial; Psoriasis; Tolerability; Internal medicine; Dermatology; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005466865,0.001814577,0.003969222,0.0005101815,0.000623635,0.001291398,0.001428062,0.002858798,0.004673449],"category_scores_gemma":[0.003770991,0.0009848516,0.002983663,0.0004648465,0.00218718,0.001556003,0.0005095502,0.004577389,0.001064794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000863954,"about_ca_system_score_gemma":0.001831059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005988009,"about_ca_topic_score_gemma":0.0009649368,"domain_scores_codex":[0.9978135,0.001291465,0.0001473938,0.0002672129,0.0002416894,0.0002387151],"domain_scores_gemma":[0.9963436,0.0009999048,0.0008691115,0.0004103907,0.000285022,0.001092046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9365048,0.03513909,0.0006098219,0.0004668491,0.0007216245,0.00005629962,0.0001629385,0.000470773,0.01363605,0.00006451208,0.0005257823,0.01164141],"study_design_scores_gemma":[0.7191408,0.2754957,0.002514612,0.00002462395,0.0003419043,0.00007137042,0.00002394208,0.0003392352,0.001600542,0.00009682884,0.0003283921,0.0000220273],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933629,0.001428757,0.0008101392,0.0002196412,0.0001303444,0.002718772,0.0004711644,0.00008286766,0.0007754336],"genre_scores_gemma":[0.9919012,0.001075886,0.001450568,0.0005622917,0.0002500123,0.002438464,0.0007450014,0.00003860053,0.001537983],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005466865,"threshold_uncertainty_score":0.02891189,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04463726408912411,"score_gpt":0.3397974502253265,"score_spread":0.2951601861362024,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}